Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by topic
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by topic
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are here
Home
Archive
Volume 8, Issue 1
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Responses
Article
metrics
Alerts
PDF
Clinical/translational cancer immunotherapy
Original research
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Online download statistics by month:
Online download statistics by month: February 2020 to December 2020
Abstract
Full
Pdf
Feb 2020
94
94
21
Mar 2020
692
692
226
Apr 2020
241
241
120
May 2020
325
325
161
Jun 2020
293
293
53
Jul 2020
262
262
65
Aug 2020
241
241
64
Sep 2020
398
398
90
Oct 2020
490
491
116
Nov 2020
421
421
165
Dec 2020
394
394
104
Total
3851
3852
1185
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF